Sensenig Bethany 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Supernus (SUPN) Director Bethany Sensenig Sells Shares & Exercises RSUs
What Happened
Bethany Sensenig, a director of Supernus Pharmaceuticals (SUPN), had 4,475 restricted stock units (RSUs) vest on February 19, 2026. Those RSUs converted into 4,475 shares (reported as an exercise/conversion, code M, at $0.00) and the shares were sold in two open‑market transactions the same day (codes S) for total proceeds of approximately $228,265 (1,217 shares at a weighted avg $50.31 → $61,227; 3,258 shares at a weighted avg $51.27 → $167,038). These sales were executed under a pre‑existing Rule 10b5‑1 trading plan.
Key Details
- Transaction date: February 19, 2026; Form 4 filed February 23, 2026 (timely).
- Sales: 1,217 shares at weighted avg $50.31 (prices ranged $49.83–$50.71); 3,258 shares at weighted avg $51.27 (prices ranged $50.98–$51.56). Total proceeds ≈ $228,265.
- Acquisition: 4,475 RSUs settled into common stock upon vesting (reported at $0.00 per share).
- Plan/footnotes: Transactions made pursuant to a 10b5‑1 plan adopted May 15, 2025; weighted average prices reflect multiple executions (reporting person will provide per‑price breakdown upon request).
- Shares owned after the transactions: not specified in the provided filing excerpt.
Context
- This was a routine vesting and sale: RSUs vested (conversion reported as a derivative transaction) and the resulting shares were sold the same day. That pattern (vest-and-sell) is typically a liquidity event rather than an outright open‑market purchase signal.
- The use of a 10b5‑1 trading plan indicates the sales were pre‑planned and automated, reducing concerns about selective timing.
Insider Transaction Report
Form 4
Sensenig Bethany
Director
Transactions
- Exercise/Conversion
Common Stock
2026-02-19+4,475→ 4,475 total - Sale
Common Stock
[F1][F2]2026-02-19$50.31/sh−1,217$61,227→ 3,258 total - Sale
Common Stock
[F1][F3]2026-02-19$51.27/sh−3,258$167,038→ 0 total - Exercise/Conversion
Restricted Stock Unit
[F4][F5]2026-02-19−4,475→ 0 total→ Common Stock (4,475 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- [F5]These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026.
Signature
/s/ Timothy C. Dec, as attorney-in-fact|2026-02-23